initiated, funded and developed by Takeda
Adverse Event reporting information can be found at the bottom of the page
initiated, funded and developed by Takeda
Explore the Elvanse Hub on BMJ
This dedicated page, hosted by BMJ and developed in partnership with Takeda, brings together expert-led content to support your understanding of adult ADHD and the role of Elvanse in clinical practice.
Access practical resources, real-world insights, and educational materials designed to help you make confident, informed treatment decisions.
Explore Takeda’s ADHD Portfolio for Children and Young People
This dedicated site brings together key information on Takeda’s licensed ADHD treatments for children and adolescents—Elvanse® (lisdexamfetamine), Intuniv®▼ (guanfacine hydrochloride), and Equasym® XL (methylphenidate).
Designed for UK healthcare professionals, the site offers clinical guidance, prescribing information, and practical resources to support confident treatment decisions across a range of patient needs.
Whether you're looking to tailor therapy by mode of action, duration, or tolerability, this platform helps you navigate options and optimise care for young people living with ADHD.
